CDI Laboratories in Mayagüez — the only company in the world using pioneering technology with the ability to generate high specificity monoclonal antibodies — began a new phase of research after receiving a combined $11.4 million in local and federal funding to develop new technologies in the field of medicine.
Looking to foster Puerto Rico’s potential in pharmaceutical innovation, drug developer Merck has partnered with the Yale School of Medicine and the Comprehensive Cancer Center at the University of Puerto Rico to launch a drug discovery and development teaching program.
Puerto Rico Puerto, the second largest investment destination in the region, is struggling to retain its position as a “viable value proposition” for pharmaceutical companies that have significantly scaled back their investments on the island in the last four years, a recently released study by Jones Lang LaSalle a global real estate services firm concluded.
A Dow Jones/Factiva content provider since 2014
Subscribe to our Dollars & Sense podcast!
